Citations

Citations to this article as recorded by  

• Etiology of Drug-Induced Edema: A Review of Dihydropyridine, Thiazolidinedione, and Other Medications Causing Edema
  Evan S Sinnathamby, Bretton T Urban, Robert A Clark, Logan T Roberts, Audrey J De Witt, Danielle M Wenger, Aya Mouhaffel, Olga Willett, Shahab Ahmadzadeh, Sahar Shekoohi, Alan D Kaye, Giustino Varrassi
  Cureus.2024;[Epub]     CrossRef
• Novel thiazolidin-4-one benzenesulfonamide hybrids as PPARγ agonists: Design, synthesis and in vivo anti-diabetic evaluation
  Islam H. Ali, Rasha M. Hassan, Ahmed M. El Kerdawy, Mahmoud T. Abo-Elfadl, Heba M.I. Abdallah, Francesca Sciandra, Iman A.Y. Ghannam
  European Journal of Medicinal Chemistry.2024; 269: 116279.     CrossRef
• The role of the methoxy group in approved drugs
  Debora Chiodi, Yoshihiro Ishihara
  European Journal of Medicinal Chemistry.2024; 273: 116364.     CrossRef
• Thiazolidinedione an auspicious scaffold as PPAR-γ agonist: its possible mechanism to Manoeuvre against insulin resistant diabetes mellitus
  Sourav Basak, Anjali Murmu, Balaji Wamanrao Matore, Partha Pratim Roy, Jagadish Singh
  European Journal of Medicinal Chemistry Reports.2024; 11: 100160.     CrossRef
• Quantitative determination of lobeglitazone sulfate and glimepiride in combined tablet by robust high‐performance thin layer chromatographic method
  Ashim Kumar Sen, Tantul Sarkar, Dhanya B. Sen, Rajesh A. Maheshwari, Aarti S. Zanwar, Rajesh L. Dumpala
  SEPARATION SCIENCE PLUS.2024;[Epub]     CrossRef
• A chemical modification of a peroxisome proliferator-activated receptor pan agonist produced a shift to a new dual alpha/gamma partial agonist endowed with mitochondrial pyruvate carrier inhibition and antidiabetic properties
  Antonio Laghezza, Carmen Cerchia, Massimo Genovese, Roberta Montanari, Davide Capelli, Judith Wackerlig, Stefan Simic, Emanuele Falbo, Lucia Pecora, Rosalba Leuci, Leonardo Brunetti, Luca Piemontese, Paolo Tortorella, Abanish Biswas, Ravi Pratap Singh, Su
  European Journal of Medicinal Chemistry.2024; 275: 116567.     CrossRef
• Efficacy and Safety of Novel Thiazolidinedione Rivoglitazone in Type-2 Diabetes a Meta-Analysis
  Deep Dutta, Jyoti Kadian, Indira Maisnam, Ashok Kumar, Saptarshi Bhattacharya, Meha Sharma
  Indian Journal of Endocrinology and Metabolism.2023; 27(4): 286.     CrossRef
• Efficacy and safety of novel thiazolidinedione lobeglitazone for managing type-2 diabetes a meta-analysis
  Deep Dutta, Saptarshi Bhattacharya, Manoj Kumar, Priyankar K. Datta, Ritin Mohindra, Meha Sharma
  Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2023; 17(1): 102697.     CrossRef
• Efficacy and safety of lobeglitazone, a new Thiazolidinedione, as compared to the standard of care in type 2 diabetes mellitus: A systematic review and meta-analysis
  Shashank R. Joshi, Saibal Das, Suja Xaviar, Shambo Samrat Samajdar, Indranil Saha, Sougata Sarkar, Shatavisa Mukherjee, Santanu Kumar Tripathi, Jyotirmoy Pal, Nandini Chatterjee
  Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2023; 17(1): 102703.     CrossRef
• Synthesis, Characterization, and Pharmacokinetic Studies of Thiazolidine-2,4-Dione Derivatives
  Bushra Ansari, Haroon Khan, Muhammad Saeed Jan, Khalaf F. Alsharif, Khalid J. Alzahrani, Umer Rashid, Abdul Saboor Pirzada, Vinod Kumar Tiwari
  Journal of Chemistry.2023; 2023: 1.     CrossRef
• Will lobeglitazone rival pioglitazone? A systematic review and critical appraisal
  Kalyan Kumar Gangopadhyay, Awadhesh Kumar Singh
  Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2023; 17(4): 102747.     CrossRef
• Evaluation of pharmacokinetic interactions between lobeglitazone, empagliflozin, and metformin in healthy subjects
  Heeyoung Kim, Choon Ok Kim, Hyeonsoo Park, Min Soo Park, Dasohm Kim, Taegon Hong, Yesong Shin, Byung Hak Jin
  Translational and Clinical Pharmacology.2023; 31(1): 59.     CrossRef
• Lobeglitazone, a novel thiazolidinedione, for secondary prevention in patients with ischemic stroke: a nationwide nested case-control study
  Joonsang Yoo, Jimin Jeon, Minyoul Baik, Jinkwon Kim
  Cardiovascular Diabetology.2023;[Epub]     CrossRef
• Complementary effects of dapagliflozin and lobeglitazone on metabolism in a diet-induced obese mouse model
  Yun Kyung Lee, Tae Jung Oh, Ji In Lee, Bo Yoon Choi, Hyen Chung Cho, Hak Chul Jang, Sung Hee Choi
  European Journal of Pharmacology.2023; 957: 175946.     CrossRef
• Thiazolidinediones: Recent Development in Analytical Methodologies
  Tarang Patel, Vatsal Patel
  Journal of Chromatographic Science.2023;[Epub]     CrossRef
• Current Clinical Trial Status and Future Prospects of PPAR-Targeted Drugs for Treating Nonalcoholic Fatty Liver Disease
  Shotaro Kamata, Akihiro Honda, Isao Ishii
  Biomolecules.2023; 13(8): 1264.     CrossRef
• Lobeglitazone inhibits LPS-induced NLRP3 inflammasome activation and inflammation in the liver
  Hye-Young Seo, So-Hee Lee, Ji Yeon Park, Eugene Han, Sol Han, Jae Seok Hwang, Mi Kyung Kim, Byoung Kuk Jang, Kenji Fujiwara
  PLOS ONE.2023; 18(8): e0290532.     CrossRef
• Insulin sensitizers in 2023: lessons learned and new avenues for investigation
  Jerry R. Colca, Steven P. Tanis, Rolf F. Kletzien, Brian N. Finck
  Expert Opinion on Investigational Drugs.2023; 32(9): 803.     CrossRef
• Treatment of type 2 diabetes mellitus with stem cells and antidiabetic drugs: a dualistic and future-focused approach
  Priyamvada Amol Arte, Kanchanlata Tungare, Mustansir Bhori, Renitta Jobby, Jyotirmoi Aich
  Human Cell.2023; 37(1): 54.     CrossRef
• Lobeglitazone and Its Therapeutic Benefits: A Review
  Balamurugan M, Sarumathy S, Robinson R
  Cureus.2023;[Epub]     CrossRef
• Diabetes and diabesity in the view of proteomics, drug, and plant-derived remedies
  Mohammad Reza Haeri
  Journal of Research in Medical Sciences.2023;[Epub]     CrossRef
• A double‐blind, Randomized controlled trial on glucose‐lowering EFfects and safety of adding 0.25 or 0.5 mg lobeglitazone in type 2 diabetes patients with INadequate control on metformin and dipeptidyl peptidase‐4 inhibitor therapy: REFIND study
  Soree Ryang, Sang Soo Kim, Ji Cheol Bae, Ji Min Han, Su Kyoung Kwon, Young Il Kim, Il Seong Nam‐Goong, Eun Sook Kim, Mi‐kyung Kim, Chang Won Lee, Soyeon Yoo, Gwanpyo Koh, Min Jeong Kwon, Jeong Hyun Park, In Joo Kim
  Diabetes, Obesity and Metabolism.2022; 24(9): 1800.     CrossRef
• Effect of the addition of thiazolidinedione to sodium-glucose cotransporter 2 inhibitor therapy on lipid levels in type 2 diabetes mellitus: a retrospective study using Korean National Health Insurance Service data
  Taegyun Park, Kyungdo Han, Dongwook Shin, Jongho Park
  Cardiovascular Prevention and Pharmacotherapy.2022; 4(3): 114.     CrossRef
• Design of Improved Antidiabetic Drugs: A Journey from Single to Multitarget Agents
  Vassiliki‐Panagiota Tassopoulou, Ariadni Tzara, Angeliki P. Kourounakis
  ChemMedChem.2022;[Epub]     CrossRef
• A Real-World Study of Long-Term Safety and Efficacy of Lobeglitazone in Korean Patients with Type 2 Diabetes Mellitus
  Bo-Yeon Kim, Hyuk-Sang Kwon, Suk Kyeong Kim, Jung-Hyun Noh, Cheol-Young Park, Hyeong-Kyu Park, Kee-Ho Song, Jong Chul Won, Jae Myung Yu, Mi Young Lee, Jae Hyuk Lee, Soo Lim, Sung Wan Chun, In-Kyung Jeong, Choon Hee Chung, Seung Jin Han, Hee-Seok Kim, Ju-Y
  Diabetes & Metabolism Journal.2022; 46(6): 855.     CrossRef
• Lobeglitazone Exerts Anti-Inflammatory Effect in Lipopolysaccharide-Induced Bone-Marrow Derived Macrophages
  Dabin Jeong, Wan-Kyu Ko, Seong-Jun Kim, Gong-Ho Han, Daye Lee, Seung-Hun Sheen, Seil Sohn
  Biomedicines.2021; 9(10): 1432.     CrossRef